85474-75-5

Basic information

• Product Name: 4-PIPERAZIN-1-YL-BENZOIC ACID
• Synonyms: CHEMBRDG-BB 4001711;4-PIPERAZIN-1-YL-BENZOIC ACID;4-(PIPERAZIN-1-YL)-BENZOIC ACID 2 HBR;4-PIPERAZIN-1-YL-BENZOIC ACID DIHYDROBROMIDE;AKOS BB-5564;RARECHEM AL BO 0956;4-(PIPERAZIN-1-YL)-BENZOIC ACID X 2 HBR 99%;4-(PIPERAZIN-1-YL)-BENZOIC ACID X 2 HBR
• CAS NO: 85474-75-5
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.24
• Product Categories: pharmacetical;piperazines
• Mol File: 85474-75-5.mol

Chemical Properties

• Melting Point: 295°C
• Boiling Point: 424.7 °C at 760 mmHg
• Flash Point: 210.6 °C
• Appearance: /
• Density: 1.211 g/cm³
• Vapor Pressure: 5.71E-08mmHg at 25°C
• Refractive Index: 1.58
• PKA: 5.02±0.10(Predicted)
• CAS DataBase Reference: 4-PIPERAZIN-1-YL-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERAZIN-1-YL-BENZOIC ACID(85474-75-5)
• EPA Substance Registry System: 4-PIPERAZIN-1-YL-BENZOIC ACID(85474-75-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 85474-75-5(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C11H14N2O2/c14-11(15)9-1-3-10(4-2-9)13-7-5-12-6-8-13/h1-4,12H,5-8H2,(H,14,15)

Upstream product

• 234082-33-8 4-(4-ethoxycarbonylphenyl)piperazine-1-carboxylic acid tert-butyl ester 
• 162046-66-4 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid 
• 451-46-7 4-fluorobenzoic acid ethyl ester 

Downstream Products

• 1018631-34-9 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid 
• 1374882-66-2 {(S)-1-[(S)-2-(4-{4'-[4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester 
• 1374891-49-2 N-(4-bromo-phenyl)-4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzamide 
• 1374891-52-7 (S)-2-(4-{4'-[4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Piperazine-substituted aryl and aralkyl carboxylic acids useful for treating infirmaties caused by excess lipids or thrombocyte

The present invention is concerned with new carboxylic acid derivatives, with processes for the preparation thereof and with pharmaceutical compositions for lipid depression and thrombocyte aggregation, containing them, and to methods for treating infirmaties caused by excess lipids or thrombocyte aggregation. The new carboxylic acid derivatives according to the present invention are compounds of the general formula: STR1 wherein A is a valency bond or a lower alkylene chain, B is a valency bond or a saturated or unsaturated lower alkylene chain, R is hydrogen, an alkyl group which can be substituted by hydroxyl, carboxyl, sulphonic acid or optionally substituted phenoxy group, or R is an aralkyl radical, the aryl moiety of which can be substituted and the alkyl moiety of which is optionally unsaturated and can contain up to 4 carbon atoms, or R is a phenacyl radical, the phenyl moiety optionally substituted, or R is an acyl radical derived from aliphatic, araliphatic or aromatic carboxylic or sulphonic acid, or R is an aryl radical optionally substituted with the proviso that when A is a valency bond, R cannot be hydrogen, methyl, ethyl, hydroxyethyl, benzyl or phenyl, and the physiologically acceptable salts, esters and amides thereof.